Presented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer Research (AACR) Annual MeetingDosed first patient in Phase 1b combination study of...
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
NEWTOWN SQUARE, Pa., Oct. 30, 2023 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical...
InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib